Drug Database for Digestive Cancers

We often receive the question: ‘which drugs or pharmaceutical treatments (chemotherapy, immunotherapy) are available for patients with digestive cancers? What drugs are available for bowel cancer or colorectal cancer, for gastric cancer, for oesophageal cancer, for liver cancer, pancreatic cancer or for rare digestive cancers?’ This database can give you an indication and answers.

It’s simple to use the database:

  1. Select which type of digestive cancer you want information about via: ‘Type of Cancer’
  2. Select whether you are looking for treatments that are still ‘In Development’ or ‘Approved for Market Access’*

*In Development means that these compounds are currently being researched in Phase II (small group of patients) or Phase III (large group of patients). This information is derived from international analyses and from the individual companies involved.

Approved for Market Access means that the European Medicines Agency (EMA) has approved this drug for marketing in the European Union. It does not necessarily mean that this treatment is already available in your country.

Please note the following about the database:

  • It is possible that one molecule is already approved for one indication (for instance colorectal cancer) but not yet approved for another type of cancer (for instance gastric cancer).
  • In the list you can also see which companies are the ‘marketing authorisation holder’ for the treatment or the developer of the compound, and in which country their headquarters are located.
  • It is only indicative and several of the drugs mentioned are indicated for small subpopulations of the cancer mentioned. Please discuss these options with your treating medical team if you want more information on whether it is suitable for you or available.
  • ‘Country’ in the table identifies the country of origin of the company developing or selling the medicine
  • It is updated once a year, but please let us know if more urgent changes need to be made.
Drug Company Country
Masitinib (AB-1010) AB Science France gastric cancer, colorectal cancer
Capecitabine (generic) Accord Healthcare United Kingdom gastric cancer, colorectal cancer
Lutathera (lutetium Lu 177 dotatate) (NET) Advanced Accelerator Applications (Novartis) United States rare cancer
Ivosidenib Agios Pharmaceuticals United States liver cancer
Trastuzumab biosimilar Allergan Ireland gastric cancer
Vectibix (Panitumumab) Amgen United States colorectal cancer
Kanjinti (Trastuzumab biosimilar) Amgen United States gastric cancer
Mvasi (Bevacizumab) Amgen United States colorectal cancer
AMG 510 (II) Amgen United States colorectal cancer
Crenolanib (GIST) (III) AROG Pharmaceuticals United States gastric cancer
Derazantinib (ARQ 087) (III) ArQule United States liver cancer
Encorafenib (BRAF inhibitor) Array Biopharmaceuticals United States colorectal cancer
Ipatasertib Array Biopharmaceuticals United States colorectal cancer
Varlitinib (II/III) Aslan Pharmaceuticals Singapore biliary tract cancer
IMAB362 (zolbetuximab) Astellas Japan oesophageal cancer, gastric cancer
Lynparza POLO AstraZeneca United Kingdom/Sweden pancreatic cancer
Imfinzi (Durvalumab ) AstraZeneca United Kingdom/Sweden oesophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer
Lynparza (II) AstraZeneca United Kingdom/Sweden gastric cancer
Imfinzi (Durvalumab) (II) AstraZeneca United Kingdom/Sweden oesophageal cancer, gastric cancer, liver cancer, biliary tract cancer
Tremelimumab (II) AstraZeneca United Kingdom/Sweden oesophageal cancer, gastric cancer, colorectal cancer
Stivarga (Regorafenib) Bayer Germany gastric cancer, liver cancer, biliary tract cancer, rare cancer
Nexavar(Sorafenib) Bayer Germany liver cancer
Vitrakvi (Larotrectinib) (NTRK) Bayer Germany oesophageal cancer, gastric cancer, colorectal cancer, liver cancer, biliary tract cancer, rare cancer
Selitrectinib Bayer Germany oesophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer, liver cancer, biliary tract cancer, rare cancer
Stivarga (Regorafenib) (II) Bayer Germany biliary tract cancer
Tislelizumab (BGB-A317) (III) BeiGene China liver cancer
Opdivo (Nivolumab) BMS United States colorectal cancer
Taxol BMS United States pancreatic cancer
Yervoy (Ipilimumab) BMS United States colorectal cancer
Opdivo (Nivolumab) BMS United States oesophageal cancer, gastric cancer, colorectal cancer
BMS-986183 (II) BMS United States liver cancer
Linrodostat (BMS-986205) (II) BMS United States gastric cancer
Relatlimab (II) BMS United States gastric cancer, colorectal cancer
Yervoy (Ipilumab) (III) BMS United States oesophageal cancer, gastric cancer, colorectal cancer
Bevacizumab Biosimilar (BI 695502) Boehringer Ingelheim Germany colorectal cancer
Napabucasin (BBI-608) Boston Biomedical United States colorectal cancer
Napabucasin (II) Boston Biomedical United States gastric cancer
Amcasertib (BBI503) Boston Biomedical United States liver cancer
Namodenoson (CF102) Can-Fite BioPharma Israel liver cancer
Polyclonal antibody stimulator (III) Cancer Advances United States gastric cancer
Onvansertib (II) Cardiff Oncology United States colorectal cancer
ENMD-2076 (II) CASI Pharmaceuticals China liver cancer
Abraxane Celgene United States gastric cancer, pancreatic cancer
Tislelizumab (BGB-A317) Celgene United States oesophageal cancer
Herzuma (trastuzumab biosimilar) Celltrion Korea gastric cancer
ThermoDox (doxorubicin liposomal) (III) Celsion United States liver cancer
Trastuzumab Deruxtecan (DS-8201) (II) Daiichi Sankyo Japan gastric cancer, colorectal cancer
DCC-2618 (GIST - III) Deciphera Pharmaceuticals United States gastric cancer
eFT508 (II) eFFECTOR Therapeutics United States liver cancer
Lenvima (Lenvatinib) Eisai Japan liver cancer
Rivoceranib (III) Elevar Therapeutics Korea gastric cancer
Andecaliximab (II) Gilead United States gastric cancer
bintrafusp alfa GSK United Kingdom biliary tract cancer
INCB54828 (II) InCyte United States liver cancer
INCB62079 (II) InCyte United States liver cancer
Somatuline Ipsen France rare cancer
Cabozantinib (Cabometyx) Ipsen France liver cancer
eFT508 (MKNK1/MKNK2 protein inhibitor) Isofol Medical AB Sweden colorectal cancer
Modufolin (arfolitixorin) (III) Isofol Medical AB Sweden colorectal cancer
Erdafinitib Janssen United States oesophageal cancer, gastric cancer
Imbruvica (ibrutinib) (III) Janssen United States pancreatic cancer
Famitinib (III) Jiangsu HengRui Medicine China colorectal cancer
Ecansya (generic Capecitabine) Krka Slovenia gastric cancer, colorectal cancer
DKN-01 (anti-DKK1 mAb) (II) Leap Therapeutics United States biliary tract cancer
Cyramza (Ramucirumab) Lilly United States oesophageal cancer, gastric cancer, colorectal cancer, liver cancer
Gemzar Lilly United States pancreatic cancer
Erbitux Lilly United States colorectal cancer
Phase III Lilly United States pancreatic cancer
galunisertib (II) Lilly United States liver cancer
merestinib (II) Lilly United States biliary tract cancer
Vinorelbine Tartrate (II) Lilly United States colorectal cancer
Capecitabine (generic) Medac Germany gastric cancer, colorectal cancer
Erbitux (Cetuximab) Merck Germany colorectal cancer
Peposertib (M3814, DNA-PK inhibitor) (Phase II) Merck Germany colorectal cancer
Bintrafusp Alfa (II and II/III) Merck Germany biliary tract cancer
Keytruda Phase III MSD United States oesophageal cancer, gastric cancer, colorectal cancer, liver cancer, biliary tract cancer
Keytruda Phase II (dMMR) MSD United States rare cancer
Lynparza phase III MSD United States pancreatic cancer
Ogivri (Trastuzumab biosimilar) Mylan/Upjohn United States gastric cancer
NC-6004 (II) NanoCarrier Japan liver cancer
Teysuno (Tegafur/Gimeracil/Oteraci) Nordic Group France gastric cancer
Afinitor Novartis Switzerland gastric cancer, pancreatic cancer
Gleevec Novartis Switzerland rare cancer
Capmatinib (INC280) (II) FGF401 (II) Novartis Switzerland liver cancer
VPM087 (1L) (II) Novartis Switzerland colorectal cancer
Tafinlar (Dabrafenib) Novartis Switzerland rare cancer
Mekinist (Trametinib) Novartis Switzerland rare cancer
Ellence (Epirubicin) Pfizer United States gastric cancer
Camptosar (Irinotecan) Pfizer United States gastric cancer, colorectal cancer
Sutent Pfizer United States rare cancer
Trazimera (Trastuzumab biosimilar) Pfizer United States oesophageal cancer, gastric cancer
Zirabev (Bevacizumab) Pfizer United States colorectal cancer
PM184 (II) PharmaMar Spain colorectal cancer
Binimetinib (MEK162) Pierre Fabre France colorectal cancer
ensituximab Precision Biologics United States colorectal cancer
Infigratinib (BGJ398) QED Therapeutics United States liver cancer
ABC294640 (Yeliva®) Redhill BioPharma United States liver cancer
Herceptin® (Trastuzumab) Roche Switzerland oesophageal cancer, gastric cancer
Avastin® (Bevacizumab) Roche Switzerland colorectal cancer
Tarceva® (Erlotinib) Roche Switzerland pancreatic cancer
Xeloda® (Capecitabine) Roche Switzerland colorectal cancer
Tecentriq® (Atezolizumab) Roche Switzerland colorectal cancer
Tecentriq® (Atezolizumab) (Ib/II) Roche Switzerland oesophageal cancer, gastric cancer, pancreatic cancer
Tecentriq® (Atezolizumab) (III) Roche Switzerland liver cancer
Tiragolumab (Ib/II) Roche Switzerland oesophageal cancer, pancreatic cancer
Cotellic® (Cobimetinib) (Ib/II) Roche Switzerland gastric cancer, pancreatic cancer
Cotellic® (Cobimetinib) Roche Switzerland colorectal cancer
Avastin® (Bevacizumab) (I) Roche Switzerland colorectal cancer
Avastin® (Bevacizumab) (Ib/II) Roche Switzerland pancreatic cancer
Avastin® (Bevacizumab) (III) Roche Switzerland liver cancer
Cibisatamab (I) Roche Switzerland colorectal cancer
Selicrelumab (Ib/II) Roche Switzerland pancreatic cancer
RO6874281 (Ib/II) Roche Switzerland pancreatic cancer
Ontruzant (Trastuzumab biosimilar) Samsung Bioepis Korea gastric cancer
5- Fluorouracil (generic) Sandoz Switzerland gastric cancer, colorectal cancer
Capecitabine (generic) Sandoz Switzerland gastric cancer, colorectal cancer
Docetaxel (generic) Sandoz Switzerland gastric cancer
Oxaliplatin (generic) Sandoz Switzerland colorectal cancer
Caclium Folinate (generic) Sandoz Switzerland colorectal cancer
Irinotecan (generic) Sandoz Switzerland colorectal cancer
Gemcitabine (generic) Sandoz Switzerland pancreatic cancer
Trastuzumab biosimilar Sandoz Switzerland gastric cancer
Taxotere (docetaxel) Sanofi France oesophageal cancer, gastric cancer
Eloxatin (folfox) Sanofi France colorectal cancer
Zaltrap (Ziv-Aflibercept) Sanofi France colorectal cancer
Lonsurf Servier France colorectal cancer, pancreatic cancer
Lonsurf (Tipiracil/Trifluridine) (III) Servier France gastric cancer
Onivyde Servier France colorectal cancer
Ph II & Onivyde (PhIII) Servier France pancreatic cancer, rare cancer
Lonsurf (1L) Servier France gastric cancer, colorectal cancer
Pexastimogene Devacirepvec (Pexa-Vec) (III) SillaJen Biotherapeutics Korea liver cancer
Donafenib (III) Suzhou Zelgen Biopharmaceuticals Co China colorectal cancer
Entinostat (II) Syndax Pharmaceuticals United States colorectal cancer
CMAB009 (III) Taizhou Mabtech Pharmaceutical China colorectal cancer
Tirapazamine (TPZ) (II) Teclison United States/Taiwan liver cancer
Capecitabine (generic) Teva Israel gastric cancer, colorectal cancer
TRC-105 (II) TRACON Pharmaceuticals United States liver cancer

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.
Skip to toolbar